 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA, a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system CNS in both rare and large patient populations, today announced it will host a virtual key opinion leader KOL webinar on TSHA-102 for the treatment of Rett syndrome on Wednesday, September 22, 2021, from 10:00 a.m. to 12:30 p.m. ET. Th 